1. Home
  2. GBIO vs PDEX Comparison

GBIO vs PDEX Comparison

Compare GBIO & PDEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • PDEX
  • Stock Information
  • Founded
  • GBIO 2016
  • PDEX 1978
  • Country
  • GBIO United States
  • PDEX United States
  • Employees
  • GBIO N/A
  • PDEX N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • PDEX Medical/Dental Instruments
  • Sector
  • GBIO Health Care
  • PDEX Health Care
  • Exchange
  • GBIO Nasdaq
  • PDEX Nasdaq
  • Market Cap
  • GBIO 165.5M
  • PDEX 139.1M
  • IPO Year
  • GBIO 2020
  • PDEX N/A
  • Fundamental
  • Price
  • GBIO $1.67
  • PDEX $46.01
  • Analyst Decision
  • GBIO Strong Buy
  • PDEX Strong Buy
  • Analyst Count
  • GBIO 2
  • PDEX 1
  • Target Price
  • GBIO $7.50
  • PDEX $52.00
  • AVG Volume (30 Days)
  • GBIO 137.7K
  • PDEX 48.1K
  • Earning Date
  • GBIO 11-06-2024
  • PDEX 10-31-2024
  • Dividend Yield
  • GBIO N/A
  • PDEX N/A
  • EPS Growth
  • GBIO N/A
  • PDEX 1.56
  • EPS
  • GBIO N/A
  • PDEX 1.49
  • Revenue
  • GBIO $18,582,000.00
  • PDEX $56,798,000.00
  • Revenue This Year
  • GBIO $99.36
  • PDEX $3.05
  • Revenue Next Year
  • GBIO N/A
  • PDEX $2.02
  • P/E Ratio
  • GBIO N/A
  • PDEX $31.59
  • Revenue Growth
  • GBIO 514.08
  • PDEX 21.01
  • 52 Week Low
  • GBIO $1.06
  • PDEX $15.70
  • 52 Week High
  • GBIO $4.65
  • PDEX $49.98
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 32.17
  • PDEX 70.86
  • Support Level
  • GBIO $2.14
  • PDEX $40.02
  • Resistance Level
  • GBIO $2.57
  • PDEX $49.98
  • Average True Range (ATR)
  • GBIO 0.19
  • PDEX 3.29
  • MACD
  • GBIO -0.04
  • PDEX 1.15
  • Stochastic Oscillator
  • GBIO 1.23
  • PDEX 80.11

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About PDEX Pro-Dex Inc.

Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.

Share on Social Networks: